Hims & Hers Health Stock Is Tumbling Thursday: Here's Why
Hims & Hers Health Stock Is Tumbling Thursday: Here's Why
"FDA confirmed with the drug's manufacturer that their stated product availability and manufacturing capacity can meet the present and projected national demand. Patients and prescribers may still see intermittent localized supply disruptions as the products move through the supply chain from the manufacturer and distributors to local pharmacies," the FDA said.Hims & Hers Health Inc (NYSE:HIMS) shares are trading lower Thursday in possible sympathy with Eli Lilly And Co's (NYSE:LLY), after the U.S. Food and Drug Administration removed it from the weight-loss and diabetes drugs shortage list.
Hims & Hers Health Inc（纽交所：HIMS）股价周四低开，可能是出于对礼来公司（纽交所：LLY）的同情，此前美国食品和药物管理局将礼来公司的减重和糖尿病药物移出短缺清单。
What Happened: The FDA said in a statement late Wednesday that Eli Lilly's supply of Mounjaro, which is used to treat diabetes, and weight-loss drug Zepbound can now keep up with current demand.
事件经过：FDA周三晚间发布声明称，礼来公司的治疗糖尿病药物Mounjaro和减重药物Zepbound的供应现在可以满足当前需求。
Mounjaro had been on the regulator's shortage list since late 2022, and Zepbound had been on the list since April.
Mounjaro自2022年底起被列入监管机构的短缺清单，Zepbound自4月起被列入清单。
"FDA confirmed with the drug's manufacturer that their stated product availability and manufacturing capacity can meet the present and projected national demand. Patients and prescribers may still see intermittent localized supply disruptions as the products move through the supply chain from the manufacturer and distributors to local pharmacies," the FDA said.
“FDA已与药品生产商确认，他们所述的产品供应和制造能力可以满足目前和未来的国家需求。患者和处方医师可能仍会在产品从生产商和分销商到当地药店的供应链中移动时看到间歇性的局部供应中断，”FDA表示。
Hims & Hers Health shares are under pressure on Thursday as the firm sells cheaper versions of the aforementioned drugs, known as compounded drugs. Hims & Hers said in May that it would begin selling compounded versions of GLP-1 injections. Shares surged on the news and have more than doubled since the start of the year.
Hims & Hers Health股价周四受到压力，因为该公司销售所述药物的更便宜版本，即混合药物。Hims & Hers在5月表示将开始销售GLP-1注射液的混合版本。股价在这一消息的刺激下飙升，自年初以来增长超过一倍。
Don't Miss: EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO
不要错过：独家：Tema etf首席执行官预测GLP-1减重药物可能会成为一个万亿美元的市场。
The limited supply for weight-loss and diabetes drugs from Lilly and rival Novo Nordisk A/S (NYSE:NVO) sparked a demand boom for compounded drugs, which are made by combining, mixing, or altering drug ingredients, per Reuters.
礼来和竞争对手诺和诺德（纽交所：NVO）的减重和糖尿病药物供应有限引发了对混合药物的需求激增，这些药物是通过结合、混合或改变药物成分制成的，据路透社报道。
The report also indicates that regulators allow compounded versions of drugs to enter the market to meet demand when there is a shortage. When there is no shortage, compounded drug makers are reportedly unable to make "regular or inordinate amounts" of the drugs.
该报告还显示，监管机构允许混合药物的版本进入市场，以满足需求，当存在短缺时。当没有短缺时，据报道，混合药品制造商无法生产“正常或过量的”药物。
Lilly reportedly began selling vials of its lowest dose of Zepbound in the U.S. directly to consumers via its website to help push back against the rise of compounded versions of the drug. Novo Nordisk's drugs were still listed on the FDA's shortage list as of Thursday.
据报道，礼来开始直接向美国消费者销售其最低剂量的Zepbound小瓶，以帮助抵制药物复配版本的崛起。 直至周四，诺和诺德的药品仍然列在美国食品药品监督管理局的短缺名单上。
HIMS Price Action: Hims & Hers Health shares were down 8.92% at $17.26 at the time of publication, according to Benzinga Pro.
HIMS股价走势：据Benzinga Pro报道，截至发稿时，Hims & Hers Health股价下跌8.92%，报17.26美元。
Photo: Natalia Varlei from Shutterstock.
照片：来自shutterstock的Natalia Varlei。
